Cargando…
A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
The combination of oral anticoagulants (OAC) and dual antiplatelet therapy (DAPT) is the mainstay for the treatment of patients with atrial fibrillation (AF) presenting with acute coronary syndrome (ACS) and/or undergoing PCI. However, this treatment leads to a significant increase in risk of bleedi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323399/ https://www.ncbi.nlm.nih.gov/pubmed/35887851 http://dx.doi.org/10.3390/jcm11144089 |
_version_ | 1784756540932096000 |
---|---|
author | Giubilato, Simona Lucà, Fabiana Pozzi, Andrea Caretta, Giorgio Cornara, Stefano Pilleri, Anna Di Nora, Concetta Amico, Francesco Di Matteo, Irene Favilli, Silvia Rossini, Roberta Riccio, Carmine Colivicchi, Furio Gulizia, Michele Massimo |
author_facet | Giubilato, Simona Lucà, Fabiana Pozzi, Andrea Caretta, Giorgio Cornara, Stefano Pilleri, Anna Di Nora, Concetta Amico, Francesco Di Matteo, Irene Favilli, Silvia Rossini, Roberta Riccio, Carmine Colivicchi, Furio Gulizia, Michele Massimo |
author_sort | Giubilato, Simona |
collection | PubMed |
description | The combination of oral anticoagulants (OAC) and dual antiplatelet therapy (DAPT) is the mainstay for the treatment of patients with atrial fibrillation (AF) presenting with acute coronary syndrome (ACS) and/or undergoing PCI. However, this treatment leads to a significant increase in risk of bleeding. In most cases, according to the most recent guidelines, triple antithrombotic therapy (TAT) consisting of OAC and DAPT, typically aspirin and clopidogrel, should be limited to one week after ACS and/or PCI (default strategy). On the other hand, in patients with a high ischemic risk (i.e., stent thrombosis) and without increased risk of bleeding, TAT should be continued for up to one month. Direct oral anticoagulants (DOAC) in triple or dual antithrombotic therapy (OAC and P2Y12 inhibitor) should be favored over vitamin K antagonists (VKA) because of their favorable risk/benefit profile. The choice of the duration of TAT (one week or one month) depends on a case-by-case evaluation of a whole series of hemorrhagic or ischemic risk factors for each patient. Likewise, the specific DOAC treatment should be selected according to the clinical characteristics of each patient. We propose a series of paradigmatic clinical cases to illustrate the decision-making work-up in clinical practice. |
format | Online Article Text |
id | pubmed-9323399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93233992022-07-27 A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series Giubilato, Simona Lucà, Fabiana Pozzi, Andrea Caretta, Giorgio Cornara, Stefano Pilleri, Anna Di Nora, Concetta Amico, Francesco Di Matteo, Irene Favilli, Silvia Rossini, Roberta Riccio, Carmine Colivicchi, Furio Gulizia, Michele Massimo J Clin Med Article The combination of oral anticoagulants (OAC) and dual antiplatelet therapy (DAPT) is the mainstay for the treatment of patients with atrial fibrillation (AF) presenting with acute coronary syndrome (ACS) and/or undergoing PCI. However, this treatment leads to a significant increase in risk of bleeding. In most cases, according to the most recent guidelines, triple antithrombotic therapy (TAT) consisting of OAC and DAPT, typically aspirin and clopidogrel, should be limited to one week after ACS and/or PCI (default strategy). On the other hand, in patients with a high ischemic risk (i.e., stent thrombosis) and without increased risk of bleeding, TAT should be continued for up to one month. Direct oral anticoagulants (DOAC) in triple or dual antithrombotic therapy (OAC and P2Y12 inhibitor) should be favored over vitamin K antagonists (VKA) because of their favorable risk/benefit profile. The choice of the duration of TAT (one week or one month) depends on a case-by-case evaluation of a whole series of hemorrhagic or ischemic risk factors for each patient. Likewise, the specific DOAC treatment should be selected according to the clinical characteristics of each patient. We propose a series of paradigmatic clinical cases to illustrate the decision-making work-up in clinical practice. MDPI 2022-07-14 /pmc/articles/PMC9323399/ /pubmed/35887851 http://dx.doi.org/10.3390/jcm11144089 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Giubilato, Simona Lucà, Fabiana Pozzi, Andrea Caretta, Giorgio Cornara, Stefano Pilleri, Anna Di Nora, Concetta Amico, Francesco Di Matteo, Irene Favilli, Silvia Rossini, Roberta Riccio, Carmine Colivicchi, Furio Gulizia, Michele Massimo A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title_full | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title_fullStr | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title_full_unstemmed | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title_short | A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series |
title_sort | tailored antithrombotic approach for patients with atrial fibrillation presenting with acute coronary syndrome and/or undergoing pci: a case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323399/ https://www.ncbi.nlm.nih.gov/pubmed/35887851 http://dx.doi.org/10.3390/jcm11144089 |
work_keys_str_mv | AT giubilatosimona atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT lucafabiana atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT pozziandrea atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT carettagiorgio atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT cornarastefano atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT pillerianna atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT dinoraconcetta atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT amicofrancesco atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT dimatteoirene atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT favillisilvia atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT rossiniroberta atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT ricciocarmine atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT colivicchifurio atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT guliziamichelemassimo atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT atailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT giubilatosimona tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT lucafabiana tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT pozziandrea tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT carettagiorgio tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT cornarastefano tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT pillerianna tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT dinoraconcetta tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT amicofrancesco tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT dimatteoirene tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT favillisilvia tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT rossiniroberta tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT ricciocarmine tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT colivicchifurio tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT guliziamichelemassimo tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries AT tailoredantithromboticapproachforpatientswithatrialfibrillationpresentingwithacutecoronarysyndromeandorundergoingpciacaseseries |